A citation-based method for searching scientific literature

Marc Evans, Debbie Hicks, Dipesh Patel, Vinod Patel, Phil McEwan, Umesh Dashora.  2020
Times Cited: 4







List of co-cited articles
6 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range.
Tadej Battelino, Thomas Danne, Richard M Bergenstal, Stephanie A Amiel, Roy Beck, Torben Biester, Emanuele Bosi, Bruce A Buckingham, William T Cefalu, Kelly L Close,[...]. Diabetes Care 2019
230
50

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Diabetes Care 2018
53
50

Insulin-associated weight gain in diabetes--causes, effects and coping strategies.
David Russell-Jones, Rehman Khan. Diabetes Obes Metab 2007
257
50

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.
Chantal Mathieu, Paresh Dandona, Pieter Gillard, Peter Senior, Christoph Hasslacher, Eiichi Araki, Marcus Lind, Stephen C Bain, Serge Jabbour, Niki Arya,[...]. Diabetes Care 2018
75
50

Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2.
Chantal Mathieu, Paresh Dandona, Moshe Phillip, Tal Oron, Marcus Lind, Lars Hansen, Fredrik Thorén, John Xu, Anna Maria Langkilde. Diabetes Care 2019
17
50

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Steven C Griffen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Lancet Diabetes Endocrinol 2017
113
50

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N. Engl. J. Med. 2019
875
25



Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N. Engl. J. Med. 2015
25

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N. Engl. J. Med. 2017
25



SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.
Ele Ferrannini, Anna Solini. Nat Rev Endocrinol 2012
214
25

Type 1 diabetes.
Linda A DiMeglio, Carmella Evans-Molina, Richard A Oram. Lancet 2018
100
25

Type 1 diabetes mellitus.
Anastasia Katsarou, Soffia Gudbjörnsdottir, Araz Rawshani, Dana Dabelea, Ezio Bonifacio, Barbara J Anderson, Laura M Jacobsen, Desmond A Schatz, Åke Lernmark. Nat Rev Dis Primers 2017
170
25

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
D M Nathan, S Genuth, J Lachin, P Cleary, O Crofford, M Davis, L Rand, C Siebert. N. Engl. J. Med. 1993
25

Correlates of insulin injection omission.
Mark Peyrot, Richard R Rubin, Davida F Kruger, Luther B Travis. Diabetes Care 2010
223
25

Epidemiology and correlates of weight worry in the multinational Diabetes Attitudes, Wishes and Needs study.
Mark Peyrot, Soren E Skovlund, Ruediger Landgraf. Curr Med Res Opin 2009
29
25


Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52-week results from a randomized, open-label, phase III clinical trial.
Eiichi Araki, Hirotaka Watada, Yasuko Uchigata, Osamu Tomonaga, Hitomi Fujii, Hiroshi Ohashi, Tadashi Okabe, Michiko Asano, Fredrik Thoren, Hyosung Kim,[...]. Diabetes Obes Metab 2020
2
50


Hypoglycemia, diabetes, and cardiovascular events.
Cyrus V Desouza, Geremia B Bolli, Vivian Fonseca. Diabetes Care 2010
215
25

Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.
Chantal Mathieu, Bernard Zinman, Joanna Uddén Hemmingsson, Vincent Woo, Peter Colman, Erik Christiansen, Martin Linder, Bruce Bode. Diabetes Care 2016
72
25

HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study.
Thomas Danne, Bertrand Cariou, Phillip Banks, Michael Brandle, Helmut Brath, Edward Franek, Jake A Kushner, Pablo Lapuerta, Darren K McGuire, Anne L Peters,[...]. Diabetes Care 2018
55
25

Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus.
David B Sacks, Mark Arnold, George L Bakris, David E Bruns, Andrea Rita Horvath, M Sue Kirkman, Ake Lernmark, Boyd E Metzger, David M Nathan. Diabetes Care 2011
230
25

Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial.
Chantal Mathieu, Gottfried Rudofsky, Moshe Phillip, Eiichi Araki, Marcus Lind, Niki Arya, Fredrik Thorén, Markus F Scheerer, Nayyar Iqbal, Paresh Dandona.  2020
6
25

Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.
Serge Jabbour, Jochen Seufert, Andre Scheen, Clifford J Bailey, Cathrina Karup, Anna M Langkilde. Diabetes Obes Metab 2018
56
25

An Effective Insulin Therapy in Combination With Sodium-Glucose Cotransporter 2 Inhibitors.
Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, Hisayuki Katsuyama.  2019
1
100

Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
John B Buse, Satish K Garg, Julio Rosenstock, Timothy S Bailey, Phillip Banks, Bruce W Bode, Thomas Danne, Jake A Kushner, Wendy S Lane, Pablo Lapuerta,[...]. Diabetes Care 2018
68
25

SGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True?
Matthew C Riddle, William T Cefalu. Diabetes Care 2018
7
25

Hyperglycemic crises in adult patients with diabetes.
Abbas E Kitabchi, Guillermo E Umpierrez, John M Miles, Joseph N Fisher. Diabetes Care 2009
559
25

Hypoglycemia in diabetes.
Philip E Cryer, Stephen N Davis, Harry Shamoon. Diabetes Care 2003
636
25

International Consensus on Use of Continuous Glucose Monitoring.
Thomas Danne, Revital Nimri, Tadej Battelino, Richard M Bergenstal, Kelly L Close, J Hans DeVries, Satish Garg, Lutz Heinemann, Irl Hirsch, Stephanie A Amiel,[...]. Diabetes Care 2017
345
25

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.
Julio Rosenstock, Jan Marquard, Lori M Laffel, Dietmar Neubacher, Stefan Kaspers, David Z Cherney, Bernard Zinman, Jay S Skyler, Jyothis George, Nima Soleymanlou,[...]. Diabetes Care 2018
72
25

SGLT inhibitor adjunct therapy in type 1 diabetes.
Rory J McCrimmon, Robert R Henry. Diabetologia 2018
28
25

Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.
Elizabeth R Seaquist, John Anderson, Belinda Childs, Philip Cryer, Samuel Dagogo-Jack, Lisa Fish, Simon R Heller, Henry Rodriguez, James Rosenzweig, Robert Vigersky. Diabetes Care 2013
627
25


Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial.
Robert R Henry, Poul Strange, Rong Zhou, Jeremy Pettus, Leon Shi, Sergey B Zhuplatov, Traci Mansfield, David Klein, Arie Katz. Diabetes Technol. Ther. 2018
17
25

Type 1 diabetes through the life span: a position statement of the American Diabetes Association.
Jane L Chiang, M Sue Kirkman, Lori M B Laffel, Anne L Peters. Diabetes Care 2014
374
25

Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.
Bo Ahrén, Irl B Hirsch, Thomas R Pieber, Chantal Mathieu, Fernando Gómez-Peralta, Troels Krarup Hansen, Areti Philotheou, Sune Birch, Erik Christiansen, Thomas Jon Jensen,[...]. Diabetes Care 2016
49
25


Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control.
Young-Sun Lee, Hee-Sook Jun. Mediators Inflamm. 2016
76
25

COVID-19 and diabetes: Can DPP4 inhibition play a role?
Gianluca Iacobellis. Diabetes Res Clin Pract 2020
86
25

Why are pregnant women susceptible to COVID-19? An immunological viewpoint.
Hong Liu, Li-Ling Wang, Si-Jia Zhao, Joanne Kwak-Kim, Gil Mor, Ai-Hua Liao. J. Reprod. Immunol. 2020
50
25



DPP4 in Diabetes.
Diana Röhrborn, Nina Wronkowitz, Juergen Eckel. Front Immunol 2015
120
25

NF-κB signaling in inflammation.
Ting Liu, Lingyun Zhang, Donghyun Joo, Shao-Cong Sun. Signal Transduct Target Ther 2017
705
25

A multi-center retrospective analysis of the effect of DPP4 inhibitors on progression-free survival in advanced airway and colorectal cancers.
Azka Ali, Alejandra Fuentes, William Paul Skelton, Yu Wang, Susan McGorray, Chintan Shah, Rohit Bishnoi, Long H Dang, Nam H Dang.  2019
4
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.